poisar

Stock

Gain Therapeutics, Inc. GANX

$2.17+2.12%

Overview

GANX market data

Price History

GANX price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$0.89
Diluted earnings per share over the trailing twelve months.
Beta
0.20
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-6,393.8%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$1.46 – $4.34
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $94.5M · P/B 6.67 · P/S 590.55.

Company News

7 captured
Gain Therapeutics Q2 EPS $(0.11) Beats $(0.14) EstimateBenzinga · Aug 11, 2026, 11:30 AM
8-K filing — Gain Therapeutics, Inc. (GANX)SEC EDGAR · Jul 16, 2026, 11:53 AM
Gain Therapeutics Appoints Terenzio Ignoni As COOBenzinga · Jul 16, 2026, 11:10 AM
Gain Therapeutics Issues CEO Letter; Expects To Fund Operations Into Q2 2027, Based On Current Operating Plans, Including Completion Of Phase 1B Open-Label Extension In October And Initiation Of A Phase 2 During Q3 2026Benzinga · Jul 16, 2026, 11:07 AM
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price TargetBenzinga · Jul 1, 2026, 11:55 AM
Gain Therapeutics Obtains FDA Clearance Of IND To Advance GT-02287 Into Phase 2 Clinical Development for Parkinson’s Disease; IND Authorization Paves The Way For Initiation Of GT-02287 Phase 2 Clinical Development In The U.S., Expected During Q3'26Benzinga · Jun 29, 2026, 8:15 PM
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert SummitGlobenewswire Inc · Jun 10, 2026, 11:15 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock